Journal of cancer immunology最新文献

筛选
英文 中文
Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions. 转移性肾细胞癌的二线全身治疗:目前的见解和未来的方向。
Journal of cancer immunology Pub Date : 2025-01-01 DOI: 10.33696/cancerimmunol.7.107
Isaac E Kim, Vivian Wong, Karie Runcie, Eric A Singer
{"title":"Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.","authors":"Isaac E Kim, Vivian Wong, Karie Runcie, Eric A Singer","doi":"10.33696/cancerimmunol.7.107","DOIUrl":"10.33696/cancerimmunol.7.107","url":null,"abstract":"<p><p>Over the past few decades, the incidence of renal cell carcinoma (RCC) has rapidly increased with a considerable portion of patients presenting with metastatic disease (mRCC) and subsequent poor prognosis. Survival drops even further for those whose diseases progress on first-line therapy including immune-checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this review, we highlight the main second-line systemic therapies including TKIs, mTOR inhibitors, ICIs, and HIF-2α inhibitors along with their mechanisms of action and supporting clinical trials. We also highlight ongoing trials investigating novel second-line therapies such as the LITESPARK-011 trial contrasting belzutifan/lenvatinib with cabozantinib and the ENTRATA study examining glutaminase inhibitors including telaglenastat. The recent wave of key clinical trials has substantially increased the therapeutic options available to patients whose diseases have progressed on ICIs or VEGFR-TKIs. However, survival outcomes and the quality of life of mRCC patients on second-line treatments are still relatively limited, indicating a need for continued innovation and drug development in the field and continued trial recruitment at high-volume cancer centers.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"7 2","pages":"81-94"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting FAK to Potentiate Immune Checkpoint Therapy in Solid Tumors. 靶向FAK增强实体肿瘤免疫检查点治疗。
Journal of cancer immunology Pub Date : 2025-01-01 DOI: 10.33696/cancerimmunol.7.109
Karly A Stanley, Sheri L Holmen
{"title":"Targeting FAK to Potentiate Immune Checkpoint Therapy in Solid Tumors.","authors":"Karly A Stanley, Sheri L Holmen","doi":"10.33696/cancerimmunol.7.109","DOIUrl":"10.33696/cancerimmunol.7.109","url":null,"abstract":"<p><p>The advent of immune checkpoint inhibition revolutionized cancer care, yet many people will fail to respond due to innate or acquired resistance. Combination therapies with immune checkpoint inhibitors are being explored to enhance their efficacy and improve patient outcomes. Focal adhesion kinase (FAK), known for its roles in cell adhesion and migration, has emerged as a potential therapeutic target due to the identification of its additional functions in cancer progression, including its ability to establish a pro-tumorigenic, immunosuppressive microenvironment. FAK has the ability to create physical barriers for immune cell infiltration and drug delivery through its regulation of blood vessel formation and extracellular matrix in the tumor stroma. Additionally, FAK has been reported to function both within tumor and immune cells to inhibit immune cell recruitment, stimulation, and function. Taken together, FAK functions within cancer to dampen immune surveillance and promote immune escape. As a result, there is mounting interest in the use of FAK inhibitors in combination with immune checkpoint inhibition for the treatment of solid tumors, and this strategy is actively being explored in the pre-clinical and clinical setting. This article reviews the ways in which FAK alters the tumor microenvironment and the cells within it in order to assess the clinical potential of co-targeting FAK and immune checkpoints.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"7 3","pages":"99-108"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12462869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145187640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers 肿瘤和宿主微生物群对泌尿系统癌症免疫疗法反应的作用
Journal of cancer immunology Pub Date : 2024-03-01 DOI: 10.33696/cancerimmunol.6.078
Jake Drobner, Krishna Doppalapudi, B. Saraiya, V. Packiam, S. Ghodoussipour
{"title":"The Role of Tumor and Host Microbiome on Immunotherapy Response in Urologic Cancers","authors":"Jake Drobner, Krishna Doppalapudi, B. Saraiya, V. Packiam, S. Ghodoussipour","doi":"10.33696/cancerimmunol.6.078","DOIUrl":"https://doi.org/10.33696/cancerimmunol.6.078","url":null,"abstract":"Introduction & Objective: The role of the microbiome in the development and treatment of genitourinary malignancies is just starting to be appreciated. Accumulating evidence suggests that the microbiome can modulate immunotherapy through signaling in the highly dynamic tumor microenvironment. Nevertheless, much is still unknown about the immuno-oncology-microbiome axis, especially in urologic oncology. The objective of this review is to synthesize our current understanding of the microbiome’s role in modulating and predicting immunotherapy response to genitourinary malignancies.\u0000\u0000Methods: A literature search for peer-reviewed publications about the microbiome and immunotherapy response in bladder, kidney, and prostate cancer was conducted. All research available in PubMed, Google Scholar, clinicaltrials.gov, and bioRxiv up to September 2023 was analyzed.\u0000\u0000Results: Significant differences in urinary microbiota composition have been found in patients with genitourinary cancers compared to healthy controls. Lactic acid-producing bacteria, such as Bifidobacterium and Lactobacillus genera, may have value in augmenting BCG responsiveness to bladder cancer. BCG may also be a dynamic regulator of PD-L1. Thus, the combination of BCG and immune checkpoint inhibitors may be an effective strategy for bladder cancer management. In advanced renal cell carcinoma, studies show that recent antibiotic administration negatively impacts survival outcomes in patients undergoing immunotherapy, while administration of CBM588, a live bacterial product, is associated with improved progression-free survival. Specific bacterial taxa, such as Streptococcus salivarius, have been linked with response to pembrolizumab in metastatic castrate-resistant prostate cancer. Fecal microbiota transplant has been shown to overcome resistance and reduce toxicity to immunotherapy; it is currently being investigated for both kidney and prostate cancers.\u0000\u0000Conclusions: Although the exact mechanism is unclear, several studies identify a symbiotic relationship between microbiota-centered interventions and immunotherapy efficacy. It is possible to improve immunotherapy responsiveness in genitourinary malignancies using the microbiome, but further research with more standardized methodology is warranted.","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"11 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140271459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of a Training Simulator for Kidney Biopsy and Tumor Removal Procedures in Complex Positioning Scenarios: The Key Challenges 复杂体位场景下肾活检和肿瘤摘除术培训模拟器的作用:关键挑战
Journal of cancer immunology Pub Date : 2024-03-01 DOI: 10.33696/cancerimmunol.6.079
Trijit Reet Adhikary, Santu Paul, Anu Jayanthi Panicker, S. Dakua
{"title":"Role of a Training Simulator for Kidney Biopsy and Tumor Removal Procedures in Complex Positioning Scenarios: The Key Challenges","authors":"Trijit Reet Adhikary, Santu Paul, Anu Jayanthi Panicker, S. Dakua","doi":"10.33696/cancerimmunol.6.079","DOIUrl":"https://doi.org/10.33696/cancerimmunol.6.079","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"59 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140271645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Tumor-derived Small Extracellular Vesicles on T cell Survival in Patients with Cancer; A Commentary. 肿瘤源性细胞外小泡对肿瘤患者T细胞存活的影响一个评论。
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.097
Theresa L Whiteside
{"title":"Effects of Tumor-derived Small Extracellular Vesicles on T cell Survival in Patients with Cancer; A Commentary.","authors":"Theresa L Whiteside","doi":"10.33696/cancerimmunol.6.097","DOIUrl":"10.33696/cancerimmunol.6.097","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 4","pages":"162-168"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11616454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142782019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer. 联合使用表皮生长因子受体和 KRAS G12C 抑制剂治疗 KRAS G12C 突变的晚期结直肠癌。
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.086
Hirotaka Miyashita, David S Hong
{"title":"Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer.","authors":"Hirotaka Miyashita, David S Hong","doi":"10.33696/cancerimmunol.6.086","DOIUrl":"10.33696/cancerimmunol.6.086","url":null,"abstract":"<p><p>KRAS is a commonly mutated gene in advanced colorectal cancer (CRC). Recently, inhibitors of KRAS G12C were developed and have shown promising efficacy for KRAS G12C mutated non-small cell lung cancer. However, KRAS G12C inhibitor monotherapy has not demonstrated excellent efficacy for KRAS G12C mutated advanced CRC due to multiple resistance mechanisms, especially receptor tyrosine kinase (RTK) signaling activation. To overcome this resistance mechanism, various combinations of epithelial growth factor receptor (EGFR) and KRAS G12C inhibitors, including panitumumab plus sotorasib, have been investigated in clinical trials. The combination of EGFR and KRAS G12C inhibitors for KRAS G12C mutated CRC demonstrated overall response rates ranging from 26% to 62.5% in seven clinical trials of phase I to III, whose data are available so far. The median progression-free survival in these trials ranged from 3.9 to 8.1 months. These efficacy data suggest that KRAS G12C inhibitor combination with EGFR inhibitors is more effective for KRAS G12C mutated advanced CRC than KRAS G12C inhibitor monotherapy. They also showed reasonable safety of the combination regimen. Based on these results, phase III clinical trials are being conducted to investigate EGFR and KRAS G12C inhibitor combinations as a first or second-line treatment for KRAS G12C mutated advanced CRC. Furthermore, other KRAS G12C inhibitors, KRAS G12D inhibitors, and pan-RAS inhibitors are being developed, which could make more patients with advanced CRC eligible for KRAS inhibition.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 2","pages":"62-69"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11340593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer. 肌肉浸润性和转移性膀胱癌围手术期免疫检查点阻断疗法
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.081
Chethan Ramamurthy, Karen M Wheeler, Shaun Trecarten, Zaineb Hassouneh, Niannian Ji, Yifen Lee, Robert S Svatek, Neelam Mukherjee
{"title":"Perioperative Immune Checkpoint Blockade for Muscle-Invasive and Metastatic Bladder Cancer.","authors":"Chethan Ramamurthy, Karen M Wheeler, Shaun Trecarten, Zaineb Hassouneh, Niannian Ji, Yifen Lee, Robert S Svatek, Neelam Mukherjee","doi":"10.33696/cancerimmunol.6.081","DOIUrl":"10.33696/cancerimmunol.6.081","url":null,"abstract":"<p><p>Checkpoint inhibitors offer promise in treating muscle-invasive and metastatic bladder cancer, but the optimal timing of their administration-neoadjuvant or adjuvant-remains unclear. To determine the efficacy of combining checkpoint inhibition with standard cisplatin-based chemotherapy, we conducted a phase II trial of neoadjuvant anti-PD-1 (αPD-1) and anti-CTLA-4 (αCTLA-4), in combination with cisplatin-gemcitabine, for patients with muscle-invasive bladder cancer prior to radical cystectomy. In addition, a novel murine model of spontaneous metastatic bladder cancer was used to compare the efficacy of neoadjuvant versus adjuvant anti-PD-L1 (αPD-L1) treatment. The clinical trial was closed prematurely due to the industry's withdrawal of drug provision. Adverse events were observed in all patients; however, serious adverse events were not observed in any patient. A complete pathologic response was observed in 50% of the 4 patients enrolled. Response to treatment was significantly associated with elevated urinary T cells including CD8<sup>+</sup> and IFNγ<sup>+</sup> CD4<sup>+</sup> T cells, suggesting potential reinforcement of immune responses by neoadjuvant αPD-1 and αCTLA-4 against bladder tumor cells. These findings suggest that combining chemotherapy and immunotherapy in the neoadjuvant setting could be safe. However, the complete response rate of this four-drug regimen was modest and emphasizes the need for randomized controlled trials to properly assess immunotherapy efficacy in the neoadjuvant setting. In corresponding murine studies, the MB49-met model consistently displayed widespread metastasis, including tumor growth in the lungs, liver, and bowel mesentery, within 20 days of subcutaneous transplantation. Mice receiving surgery plus neoadjuvant αPD-L1 or adjuvant αPD-L1 exhibited improved survival compared to those receiving only αPD-L1. However, no significant difference in survival was observed between the neoadjuvant and adjuvant αPD-L1 cohorts. Furthermore, the timing of neoadjuvant therapy administration (early vs. late) did not significantly impact survival. This study highlights the potential of perioperative immunotherapy in the treatment of locally advanced and metastatic bladder cancer.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 1","pages":"29-39"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11113005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phosphopeptide Neoantigens as Emerging Targets in Cancer Immunotherapy. 磷酸肽新抗原作为肿瘤免疫治疗的新靶点。
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.094
Tyagi Apoorvi, Patskovsky Yury, Voloshyna Iryna, Krogsgaard Michelle
{"title":"Phosphopeptide Neoantigens as Emerging Targets in Cancer Immunotherapy.","authors":"Tyagi Apoorvi, Patskovsky Yury, Voloshyna Iryna, Krogsgaard Michelle","doi":"10.33696/cancerimmunol.6.094","DOIUrl":"10.33696/cancerimmunol.6.094","url":null,"abstract":"<p><p>Protein post-translational modifications play a vital role in various cellular events essential for maintaining cellular physiology and homeostasis. In cancer cells, aberrant post-translational modifications such as glycosylation, acetylation, and phosphorylation on proteins can result in the generation of antigenic peptide variants presented in complex with MHC molecules. These modified peptides add to the class of tumorspecific antigens and offer promising avenues for targeted anti- cancer therapies. In this review, we focus on the role of phosphorylated peptides (p-peptides) in cancer immunity. We discuss the mechanisms by which the phosphorylated moiety modifies the structural features and binding properties of p-peptides with MHC, compared to their non-phosphorylated counterparts. Additionally, we review recent work on how the HLA-B*07-specific p-peptide, pMLL<sub>747-755</sub>, interacts with its cognate TCR. Altogether, p-peptides are emerging as a novel class of tumor-specific antigens, expanding the range of targets in cancer immunotherapy.</p>","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 4","pages":"135-147"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies. 矛盾的 AKT:探索 PI3K/AKT/mTOR 靶向疗法的前景与挑战。
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.089
Gennie L Parkman, Sheri L Holmen
{"title":"A Paradoxical AKT: Exploring the Promise and Challenges of PI3K/AKT/mTOR Targeted Therapies.","authors":"Gennie L Parkman, Sheri L Holmen","doi":"10.33696/cancerimmunol.6.089","DOIUrl":"10.33696/cancerimmunol.6.089","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 3","pages":"92-99"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer. 基于血液的代谢物特征用于胰腺癌个性化风险评估。
Journal of cancer immunology Pub Date : 2024-01-01 DOI: 10.33696/cancerimmunol.6.095
Ricardo A León-Letelier, Yihui Chen, Riccardo Ballaro, Ehsan Irajizad, Kim-An Do, Anirban Maitra, Jianjun Zhang, C Max Schmidt, Johannes F Fahrmann
{"title":"A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.","authors":"Ricardo A León-Letelier, Yihui Chen, Riccardo Ballaro, Ehsan Irajizad, Kim-An Do, Anirban Maitra, Jianjun Zhang, C Max Schmidt, Johannes F Fahrmann","doi":"10.33696/cancerimmunol.6.095","DOIUrl":"10.33696/cancerimmunol.6.095","url":null,"abstract":"","PeriodicalId":73633,"journal":{"name":"Journal of cancer immunology","volume":"6 4","pages":"148-153"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信